Mayne Pharma Group Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MAYNF research report →
About the company
Mayne Pharma Group Limited is an Australian-headquartered specialty pharmaceutical enterprise, engaged in the development, production, and marketing of both patented (branded) and generic drug formulations. Its commercial reach spans Australia, New Zealand, North America (covering the United States and Canada), Europe, and Asia. The company's operations are divided into four main segments: Metrics Contract Services, International, Branded Products, and Portfolio Products.
- CEO
- Aaron Gray
- IPO
- 2013
- Employees
- 450
- HQ
- Salisbury South, SA, AU
Price Chart
- Market Cap
- $134.06M
- P/E
- -2.58
- P/S
- 0.55
- P/B
- 0.64
- EV/EBITDA
- 8.62
- Div Yield
- 0.00%
- Gross Margin
- 54.83%
- Op Margin
- -11.15%
- Net Margin
- -20.44%
- ROE
- -23.02%
- ROIC
- -6.28%
- Revenue
- $408.10M · 5.14%
- Net Income
- $-93,836,000 · 46.14%
- EPS
- $-1.14 · 46.23%
- Op Income
- $-23,593,000
- FCF YoY
- 114.36%
- 52W High
- $4.00
- 52W Low
- $1.40
- 50D MA
- $1.66
- 200D MA
- $2.25
- Beta
- 1.03
- Avg Volume
- 148
Get TickerSpark's AI analysis on MAYNF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our MAYNF coverage
Recent articles, reports, and earnings notes.
No research on MAYNF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MAYNF report →Similar companies
Peers in the same neighborhood.